Retrospective Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine

Study Overview
=================
Brief Summary
-----------------
A retrospective cohort study was performed in patients with angina pectoris who were treated with oral Chinese patent medicine and Western medicine.The hospital's medical record management system was used to collect symptoms of angina pectoris, dose and frequency of nitroglycerin use, clinical biochemical test and imaging examination.To explore the clinical efficacy of Chinese patent medicine in the treatment of coronary heart disease with angina pectoris, and provide reliable data support for its clinical application.

Official Title
-----------------
Retrospective Cohort Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine

Conditions
-----------------
Atherosclerotic Heart Disease With Angina Nos

Intervention / Treatment
-----------------
* Drug: Chinese patent medicine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 35-75 years old, gender is not limited; Admission time is September 1, 2014 - September 1, 1919; Patients with coronary heart disease and angina pectoris in the Department of Cardiology or Outpatient Department, the diagnosis of angina pectoris meets the diagnostic criteria of Western medicine and the standard of TCM syndrome differentiation; Patients who met the criteria for drug treatment, the exposed group was treated with traditional Chinese medicine combined with Western medicine, and the non-exposed group was treated with Western medicine alone. Exclusion Criteria: Combined with other heart diseases, neurosis, menopausal syndrome, hyperthyroidism, cervical or vertebral artery type cervical spondylosis, gastro-oesophageal reflux disease or esophageal hiatus hernia may cause chest pain; patients with acute myocardial infarction, heart failure, myocarditis, cardiomyopathy, severe heart valve disease, liver failure or renal failure, malignant tumors and severe metabolic diseases, as well as patients with severe symptoms and uncontrollable angina; Pregnant women, lactating women or women of childbearing age who have birth requirements; Mental patients, or cognitive dysfunction; The investigator believes that there are other situations that are not suitable for the trial.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Exposed group<br>Chinese patent medicine combined with western medicine routine treatment | Drug: Chinese patent medicine<br>* Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.<br>|
| Non-exposed group<br>Western medicine routine treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms of angina |  | one year | 
| Dosage and frequency of use of nitroglycerin |  | one year | 
| Clinical biochemical indicators test |  | one year | 
| Film degree exam |  | one year |